Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BAY2965501 |
Synonyms | |
Therapy Description |
BAY2965501 inhibits diacylglycerol kinase zeta, potentially resulting in enhanced antitumor immune response and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2023;11). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BAY2965501 | BAY-2965501|BAY 2965501 | DGKZ Inhibitor 3 | BAY2965501 inhibits diacylglycerol kinase zeta, potentially resulting in enhanced antitumor immune response and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2023;11). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05614102 | Phase I | BAY2965501 | A First-in-human Study to Learn How Safe the Study Treatment BAY2965501 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | ESP | BEL | 3 |